Altre lingue OncoZenge AB

Azioni

ONCOZ

SE0015504097

Tempo differito Nasdaq Stockholm Altri mercati azionari 10:24:16 11/07/2024			Variaz. 5gg	Var. 1 gen.
3,67 ^SEK	+0,55%		-0,14%	+18,77%

21/05	OncoZenge AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
08/04	Oncozenge AB (Publ) nomina Paolo Bossi membro del Comitato Consultivo	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

OncoZenge participates in MASCC cancer care conference June 27-29	04/06
OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05
OncoZenge Appoints Anna Asplind as Phase 3 Program Manager	26/04
OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs	25/04
OncoZenge Appoints Åsa Nilsson as Clinical Research Manager	09/04
OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board	08/04
Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board	08/04
OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™	04/04
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge	04/04
Oncozenge Explores Strategic Options for Bupizeng in China	11/03
OncoZenge Explores Strategic Options for BupiZenge™ in China	11/03
OncoZenge AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
OncoZenge Seeks to Expand Patent Protection for Oral Lozenge Product BupiZenge	07/02
OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™	07/02
OncoZenge AB Files Patent Application for Strengthened IP Protection for BupiZenge	07/02
OncoZenge Seeks Priority Medicines Status for Oral Pain Treatment in Europe	02/01
OncoZenge submits application for PRIME status in the EU	02/01
OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel	13/12
Oncozenge Announces Formation of Advisory Board with Stephen Sonis and Pooja Nandwani Patel	13/12
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast	12/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue OncoZenge AB

Azioni

ONCOZ

SE0015504097

Altre lingue

Filtri